Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.
Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, Melbourne, Australia, elaborates on patient characteristics in the SURPASS-CVOT trial and how COVID-19 may impact patients in cardiovascular outcomes trial, given that this population, by definition, has comorbidities.
Transcript
What were some characteristics of the patients enrolled in SURPASS-CVOT?
The SURPASS-CVOT allows for us to now extend the investigations beyond simply looking at "Does this agent improve glucose control, weight loss, those types of things," to actually addressing, "Does it improve cardiovascular outcomes?" Patients in this study have type 2 diabetes, they have a body mass index greater than 25, and because this is a cardiovascular outcome trial, they're high cardiovascular risk. These are patients who have clinically manifested ASCVD. So that can be either previous coronary disease, previous ischemic cerebral vascular disease, or established peripheral arterial disease.
Did COVID-19 affect trial enrollment?
I think COVID-19 has presented challenges for all of us in the clinical trial space. We were fortunate that we were able to recruit patients into this study without too much difficulty. And perhaps that does reflect a lot of excitement out there in the clinical space about the potential for a therapy like tirzepatide. We also know that this is not a placebo-controlled trial, it's actually comparing to an active drug, dulaglutide. So, in a lot of ways, every patient wins in this study, as opposed to most clinical trials where half the patients get a placebo. COVID-19 also then presents challenges for us in terms of making sure that we're able to see our patients through one of those visits and follow them.
Thankfully, we've been able to do that work closely with our sites, so that's been a great effort by our sites and our patients to continue throughout the trial. And then you can imagine that COVID-19 may potentially impact the clinical events in its own right, so our our adjudication committee has had to consider COVID-19 infection in terms of how they adjudicate events. And again, that's a challenge that has been faced by a number of clinical trials in the last few years, and we're pretty confident that we've got through at least COVID-19 so far with a trial that looks like it's on its way to be able to answer the question.
In general, how can investigators address potential effects of COVID-19 on patients in a cardiovascular outcomes trial?
I think COVID-19 presents a challenge for anybody in health care and clinical trials such as this. These are high-risk patients, so we want to make sure that these patients get the right health advice. Certainly, that includes promoting that they have a vaccine status [that] is up to date. One of the really good things in clinical trials and one of the reasons why I think patients like to participate in them is that they have a much closer relationship with the site; they're seen frequently by our study nurses and our principal investigators at the site level. It's been a great opportunity during an uncertain time for everybody for patients to have that extra degree of connection with clinicians who can be keeping an eye on them above and beyond, simply filling out the forms and checking how they're going from the trial perspective.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More